Listed by the USPTO as VIVLEMORE, TRACY ANN
Tech Center 4100 • Art Units: 1600 1631 1635 1638 1644 1674 4100 4151
This examiner grants 73% of resolved cases
VIVLEMORE, TRACY ANN works in tech center 4100 and art unit 1600. The profile records 726 resolved cases, with an allowance rate of 73.0% and a median of 1035 days to allowance. The interview lift is 6.4%, showing a positive but limited association between interviews and allowance outcomes.
The principal institutional clients are The Trustees of the University of Pennsylvania, Dana-Farber Cancer Institute Inc., and King's College London. The leading firms are HOWSON & HOWSON LLP, BAUMGARTNER PATENT LAW, and Meunier Carlin & Curfman LLC. Practitioners can use the substantial case record to assess examiner tendencies, while the moderate timing and interview figures help shape expectations for prosecution in art unit 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16098845 | GENETICALLY ENGINEERED CELLS AND METHODS OF MAKING THE SAME | Final Rejection | Editas Medicine, Inc. |
| 18141278 | COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17687246 | COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17261790 | COMPOSITIONS AND METHODS INVOLVING TRANSFORMING EXTRACELLULAR VESICLES | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 17775236 | METHODS AND COMPOSITIONS RELATING TO SELECTIVE INTRACELLULAR DELIVERY OF CD38 INHIBITORS | Final Rejection | Ohio State Innovation Foundation |
| 18602622 | GENE THERAPY FOR TUBEROUS SCLEROSIS | Non-Final OA | The General Hospital Corporation |
| 18290257 | PRODUCTION OF ENGINEERED T CELLS FROM STEM CELLS | Non-Final OA | The Regents of the University of California |
| 18448807 | COMPOSITIONS AND METHODS FOR ENHANCING GAMMA DELTA T CELLS IN THE GUT | Non-Final OA | KING'S COLLEGE LONDON |
| 18448811 | COMPOSITIONS AND METHODS FOR ENHANCING GAMMA DELTA T CELLS IN THE GUT | Non-Final OA | KING'S COLLEGE LONDON |
| 18517703 | ENGINEERED LIGHT-SENSITIVE PROTEINS | Non-Final OA | California Institute of Technology |
| 17842225 | METHODS FOR TREATING EYE DISEASE | Final Rejection | The United States Government as Represented by the Department of Veterans Affairs |
| 18282694 | SPONTANEOUS RESPIRATORY BIOMATERIAL FOR TISSUE ENGINEERING | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18551038 | PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | Non-Final OA | Pfizer Inc. |
| 17627927 | Inhibitors of microRNA 451a for Treatment of Endometriosis | Non-Final OA | YALE UNIVERSITY |
| 18061633 | GENE THERAPY FOR OCULAR DISORDERS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17904899 | TREATING AUTOSOMAL DOMINANT BESTROPHINOPATHIES AND METHODS FOR EVALUATING SAME | Final Rejection | The Trustees of the University of Pennsylvania |
| 17097997 | COMPOSITIONS FOR DRG-SPECIFIC REDUCTION OF TRANSGENE EXPRESSION | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18286923 | MATERIALS AND METHODS FOR NEUROFIBROMIN 2/MERLIN (NF2) GENE THERAPY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18595527 | AAV2-MEDIATED GENE DELIVERY OF SFASL AS A NEUROPROTECTIVE THERAPY IN GLAUCOMA | Non-Final OA | Massachusetts Eye and Ear Infirmary |
| 18273631 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC FCRN | Non-Final OA | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy73.0% of resolved applications examined by Tracy Ann Vivlemore were allowed (726 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +6.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Tracy Ann Vivlemore took 1,035 days on average from filing to allowance.
Tracy Ann Vivlemore examines applications in Art Unit 1600 in Tech Center 4100.
